NRx Pharmaceuticals, Inc.
General ticker "NRXP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $55.0M (TTM average)
NRx Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 13.9%.
Estimated limits based on current volatility of 9.7%: low 4.05$, high 4.92$
Factors to consider:
- Total employees count: 3 as of 2017
- Top business risk factors: Insufficient funding, Regulatory and compliance, Limited operating history, Dependence on product success, Geopolitical risks
- Current price 25.0% above estimated high
- Earnings for 15 months up through Q1 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.79$, 3.45$]
- 2025-12-31 to 2026-12-31 estimated range: [0.76$, 3.24$]
Financial Metrics affecting the NRXP estimates:
- Positive: with PPE of -0.8 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 0 > -0.60
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term NRXP quotes
Long-term NRXP plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $1.23MM |
| Operating Expenses | $27.59MM | $19.70MM | $17.45MM |
| Operating Income | $-27.59MM | $-19.70MM | $-16.22MM |
| Non-Operating Income | $-2.56MM | $-5.42MM | $-12.40MM |
| Interest Expense | $0.12MM | $1.08MM | $0.67MM |
| R&D Expense | $13.37MM | $6.20MM | $3.78MM |
| Income(Loss) | $-30.15MM | $-25.13MM | $-28.62MM |
| Net Income(Loss)* | $-30.15MM | $-25.13MM | $-28.62MM |
| Stockholders Equity | $-11.73MM | $-23.22MM | $-15.94MM |
| Assets | $7.32MM | $3.65MM | $12.96MM |
| Operating Cash Flow | $-21.66MM | $-10.64MM | $-14.11MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-0.00MM | $0.00MM | $-2.81MM |
| Financing Cash Flow | $6.20MM | $7.49MM | $23.28MM |
| Earnings Per Share** | $-3.98 | $-2.39 | $-1.34 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.